BRINEURA® is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.
The Consumer Medicine Information (CMI) is a leaflet written for people who have been prescribed this product. This information is intended for use in Australia only and does not replace advice from a healthcare professional. You should discuss the CMI with your healthcare professional if you have any questions or concerns.
The Product Information (PI) is intended to assist healthcare professionals in making decisions about treatment and provide advice on the appropriate use of this product. This information is intended for use in Australia only.
KUVAN® is indicated for the treatment of hyperphenylalaninemia (HPA) by reducing blood phenylalanine levels in patients with phenylketonuria (PKU) or tetrahydrobiopterin (BH4) deficiency.
NAGLAZYME® is indicated for the treatment of Mucopolysaccharidosis VI (MPS VI) storage disorder, a disease in which the enzyme level of Nacetylgalactosamine 4-sulfatase is absent or lower than normal.
PALYNZIQ® is indicated for the treatment of patients with phenylketonuria (PKU) aged 16 and older, whose blood phenylalanine levels cannot be adequately controlled by other means such as by diet.
VIMIZIM® is indicated for the treatment of MPS IVA (Mucopolysaccharidosis Type IVA, Morquio A Syndrome).
VOXZOGO® is indicated for the treatment of achondroplasia in patients 2 years of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.